Ciccarelli, O;
(2019)
Multiple sclerosis in 2018: new therapies and biomarkers.
Lancet Neurology
, 18
(1)
pp. 10-12.
10.1016/S1474-4422(18)30455-1.
Preview |
Text
Ciccarelli_Multiple sclerosis in 2018_HB_OC_Clean.pdf - Accepted Version Download (533kB) | Preview |
Abstract
2018 has been a year of substantial progress in multiple sclerosis research, with breakthroughs in experimental medicine and translational research. Advances have ranged from successful clinical trials to new reports of promising biomarkers and improved understanding of the pathophysiology of multiple sclerosis. Overall, the findings from multiple sclerosis research in 2018 hold great promise for the treatment of progressive multiple sclerosis and for the availability of new biomarkers to monitor disease progression.
| Type: | Article |
|---|---|
| Title: | Multiple sclerosis in 2018: new therapies and biomarkers |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/S1474-4422(18)30455-1 |
| Publisher version: | https://doi.org/10.1016/S1474-4422(18)30455-1 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neuroinflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10065550 |
Archive Staff Only
 |
View Item |
